Disclosures for "Week 96 Analysis of the OCARINA II Study Characterizing Subcutaneous Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis"
-
Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.
-
Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for biogen. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for genentech. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for sanofi Aventis genzyme. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for emd serono. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TGA therapeutics. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for biogen. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for emd serono. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Aventis genzyme. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for genentech. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyers Squibb. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TGA therapeutics. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for biogen. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for bristol meyers squibb. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for genentech. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for sanofi aventis genzyme. Dr. Goldstick has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for emd serono. Dr. Goldstick has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TGA therapeutics. The institution of Dr. Goldstick has received research support from biogen. The institution of Dr. Goldstick has received research support from lily. The institution of Dr. Goldstick has received research support from sanofi Aventis genzyme. The institution of Dr. Goldstick has received research support from genetech.
-
Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
-
Ewa Krzystanek has nothing to disclose.
-
Dusanka Zecevic has nothing to disclose.
-
Susanne Clinch has stock in F. Hoffmann-La Roche.
-
Caroline Giacobino has received personal compensation for serving as an employee of F. Hoffmann-La Roche AG. Caroline Giacobino has stock in F. Hoffmann-La Roche AG.
-
Jay Azmi has nothing to disclose.
-
Catarina Figueiredo has nothing to disclose.
-
Diego Centonze has nothing to disclose.